HC Wainwright Rates enGene Therapeutics (ENGN) buy

HC Wainwright maintains its buy rating on ENGN, setting a $4 target price, a 125.99% upside from the current price.

By EarningsIQ Research Desk · Published Jun 16, 2026, 7:01 AM EDT · Updated Jun 17, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated enGene Therapeutics Inc. ($ENGN) "buy" with a $4 price target on June 16, 2026.

Since the rating, $ENGN is down 2.3% after 1 week, up 9.7% after 1 month and down 4.6% to date (from the $1.75 close on Jun 16, 2026).

ENGN enGene Therapeutics Inc.

$1.67 -81.13% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating on ENGN with a $4 target price on June 16, 2026.
HC Wainwright's $4 price target implies 125.99% upside from enGene Therapeutics Inc.'s ($ENGN) current $1.77 share price.
ENGN shares are trading at $1.77, reflecting ongoing interest from analysts and insiders.
Institutional activity includes significant share changes by Siren, L.L.C. and Blue Owl Capital Holdings LP.

Get $ENGN trade alerts by text

We text you when insiders, Congress or big funds trade $ENGN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated enGene Therapeutics Inc. alert may contain errors. Disclosures

On June 16, 2026, HC Wainwright reiterated its buy rating on ENGN, setting a target price of $4. Analyst Andres Y. Maldonado expressed a positive outlook for the company, which is currently trading at $1.77 per share.

Other Institutional Activity in ENGN

Several institutional investors have shown varied interest in ENGN. FCPM III Services B.V. held steady with 9,632,561 shares valued at approximately $65.6 million. Perceptive Advisors LLC slightly trimmed its position by 41,570 shares, bringing its total to 5,827,506 shares worth about $39.7 million. Siren, L.L.C. significantly increased its holdings by 1,916,895 shares, now owning 5,253,159 shares valued at $35.8 million. Blue Owl Capital Holdings LP also boosted its stake by 1,055,416 shares, reaching 4,416,353 shares with a value of $30.1 million.

Insider Buying and Selling at enGene Therapeutics Inc.

In a notable insider buying spree on January 30, 2026, several key executives acquired shares at no cost. CEO and President Ronald Harold Wilfred Cooper purchased 801,000 shares, while Chief Technology Officer Joan Connolly, Chief Development Officer Jill Buck, Chief Strategy & Ops Officer Alexander Julian Nichols, and Chief Legal Officer Lee Giguere each acquired 195,000 shares. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

HC Wainwright & Co. maintained its buy rating on ENGN, setting a $4 target on June 16, 2026. Previously, on May 14, 2026, UBS maintained a hold rating with a $2 target. Wells Fargo downgraded the stock to hold on May 8, 2026, also with a $2 target. Meanwhile, Piper Sandler downgraded it to hold with a $4 target on the same day. The analyst consensus suggests a mixed outlook, with a range of ratings from buy to hold.

Bottom Line

HC Wainwright's reiteration of its buy rating on ENGN with a $4 target reflects continued analyst interest. The stock's current trading price and recent insider buying activity suggest potential confidence in the company's future. Institutional investors have also been active, with some increasing their stakes significantly. As always, remember that analyst ratings and institutional filings provide a snapshot of past actions and sentiment, which may not reflect current market conditions.

12-month forecast